Amentum Announces Capital Markets Day on August 13, 2024
Get Alerts J Hot Sheet
Join SI Premium – FREE
CHANTILLY, Va.--(BUSINESS WIRE)-- Amentum, a leading global engineering and technology solutions provider, is pleased to announce that it will host a capital markets day on Tuesday, August 13, 2024 at 10:00 a.m. EDT, at the New York Stock Exchange in New York City. The event will showcase Amentum’s solutions and capabilities, including the synergies and benefits expected to be realized through the previously announced transaction relating to the spin-off of Jacobs’s (NYSE: J) Critical Mission Solutions and portions of its Divergent Solutions business, including the Cyber & Intelligence business, and merger with Amentum.
Amentum’s Chief Executive Officer, John Heller, and members of the executive leadership team will also discuss Amentum’s strategy and financial outlook.
A live webcast and full copy of the presentation materials will be available shortly before the event begins on the investor relations section on Amentum’s website.
About Amentum
Amentum is a global leader in engineering, project management and solutions integration, trusted to modernize government’s most critical missions. Driven to create a safer, smarter, cleaner world, we innovate as a team of inventive doers passionate about making a difference. Underpinned by a strong culture of ethics, safety and inclusivity, Amentum is fiercely committed to operational excellence and successful execution. Headquartered in Chantilly, Virginia, we have more than 35,000 employees in approximately 75 countries in all 7 continents. Visit us at amentum.com to learn how we solve what’s next.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722733218/en/
Media:
Chanel Mann
(682) 788-5685
[email protected]
Investor Relations:
Nathan Rutledge
[email protected]
Source: Amentum
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ahtna Unveils New Enterprise Operations Rebranding
- Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
- Uther Peptide Expands Third-Party Testing and Batch Transparency Program for Research Products
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share